Diagnostics & AI
Spain's first genomic screening platform for advanced breast cancer
To create a genomic screening platform for advanced breast cancer and evaluate its efficacy in increasing the probability of a patient to be included in a clinical trial that is tailored to her specific molecular tumor type.
A GDPR and HIPAA compliant multimodal platform to store, manage, standardize and harmonize data generated from the different hospitals under a federated governance model.
This study represented the first step towards using data engineering solutions to advance our understanding of cancer biomarkers. Building upon the success of Agata, Solti launched the Hope study using Genomcore's technology.
Barcelona, Spain
Solti is a leading academic research group focused on oncology clinical trials. With 77 trials, they advance cancer research, particularly in breast cancer, to improve patient outcomes. They support specialists and conduct research, dissemination, and training to enhance professionals and empower patients.
The Agata study in Spain aimed to improve access to targeted therapies for metastatic breast cancer patients. Recognizing that cost and complex diagnostics limited the use of these therapies, Agata sought to comprehensively analyze the genomic profiles of the disease. This initiative intended to broaden participation in matched-targeted clinical trials, including patients at hospitals with limited genomic testing resources.
Agata addressed challenges in multi-center research, including varying gene panels and the need for standardized MTB data analysis. Genomcore's secure, centralized platform enabled seamless collaboration and controlled access for diverse data types, ensuring GDPR/HIPAA compliance.
This prospective, multicenter, pilot study was conducted in 10 reference hospitals across Spain:
In the study, 260 patients (female and male) between 18-70 years with advanced or metastatic breast cancer were screened.
“The main objective of this study was to be able to evaluate each case thanks to the implementation of a molecular diagnosis and being able to identify the most appropriate therapy for each patient in the event that any alteration with a therapeutic target is detected in the study of their tumor.”
Our solution is certified with ISO/IEC standards 27001:2013, 27017:2020 and 27018:2020, ensuring compliance with applicable data protection laws and regulations including GDPR and HIPAA.
